FIELD: biochemistry.
SUBSTANCE: invention relates to compounds of Formula (I) or their pharmacologically acceptable salts, which destroy, inhibit or prevent the growth or spread into the surrounding tissues of cells, especially malignant cells involved in various diseases of humans and animals. A compound of formula (I) or its pharmacologically acceptable salt is proposed, where R1 and R5 are in each case independently selected from hydrogen, C1-C10 alkyl group; R2 is selected from hydrogen and C1-C10 alkyl group, optionally substituted with one or more-OR group, and C1-C10 alkoxy group, optionally substituted with one or more-OR group, while R is selected from hydrogen and C1-C10 alkyl group; R3 means hydrogen; R4 is selected from C1-C10 alkyl group. a group, optionally replaced by one or more groups selected from -NRR' and -ОR groups, С1-С10 alkoxy group, optionally substituted by one or more groups selected from -NRR' and -ОR groups, and -CONRR', while R and R' are independently selected from hydrogen in each case, С1-С10 alkyl group, optionally substituted by one or more groups selected from OH, NH2, NHCOH and the water solubilizing group; A means a heterocyclic group selected from triazolyl, oxotriazolyl, imidazolyl, oxoimidazolidinyl, pyrazolyl, pyridyl, oxopyridyl, thiazolyl, and oxopyrrolidinyl, optionally substituted by one or more groups selected fromС1-С10 alkyl, С1-С10 alkoxy, -С1-С10 alkyl-NRR', -С1-С10 alkyl-NR-CO-R', wherein R and R' are in each case independently selected from hydrogen, С1-С10 alkyl groups; В means a five-membered heteroaryl group selected from oxodiazolyl, oxazolyl, thiadiazolyl, and thiazolyl; X means N or CH; and each solubilizing group is independently selected from Structure (a), whereinе L is selected from N, M is selected from -О- and -S- and R is С1-С10 alkyl; provided that B is a thiazolyl, and is not an imidazolyl or triazolyl.
EFFECT: compounds of the invention are intended for treatment of hematological and/or proliferative disorders.
(I),
(а)
11 cl, 4 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| SELECTIVE PROTEIN KINASE INHIBITORS | 2012 |
|
RU2612972C2 |
| COMPOUNDS OF FORMULA (I) AND FORMULA (A), PHARMACEUTICAL COMPOSITION, MEDICINAL PRODUCT, USE AND METHOD OF OBTAINING COMPOUNDS OF FORMULA (I) | 2018 |
|
RU2822758C2 |
| MULTI-SUBSTITUTED AROMATIC COMPOUNDS AS THROMBIN INHIBITORS | 2011 |
|
RU2639876C2 |
| DERIVATIVES OF 5-MEMBER HETEROCYCLES AS KINASE p38 INHIBITORS | 2004 |
|
RU2381219C2 |
| INHIBITOR COMPOUNDS | 2013 |
|
RU2673079C2 |
| PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS | 2019 |
|
RU2806758C2 |
| METHOD FOR INHIBITION OF RAF KINASE-MEDIATED GROWTH OF TUMOR CELLS, HETEROCYCLIC UREA DERIVATIVES (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) | 1998 |
|
RU2232015C2 |
| COMPOUNDS AND COMPOSITIONS AS TRO MIMETICS | 2006 |
|
RU2385865C2 |
| HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 2017 |
|
RU2742115C2 |
| METHOD FOR PREPARING DIHYDROINDENAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND USING THEM AS PROTEIN KINASE INHIBITOR | 2009 |
|
RU2528408C2 |
